HTA262 Cost Effectiveness Analysis of Paclitaxel Micellar for Treatment of First Relapse Platinum Sensitive Ovarian Cancer
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1719
https://www.valueinhealthjournal.com/article/S1098-3015(22)03924-9/fulltext
Title :
HTA262 Cost Effectiveness Analysis of Paclitaxel Micellar for Treatment of First Relapse Platinum Sensitive Ovarian Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03924-9&doi=10.1016/j.jval.2022.09.1719
First page :
Section Title :
Open access? :
No
Section Order :
11272